Early clinical trials of PD-1/PD-L1 inhibitors in breast cancer focused on TNBC, as TNBC has a higher level of tumor infiltrating lymphocytes (TILs) [8–10] and PD-L1 expression as compared to other breast cancer subtypes, suggesting that a subset of TNBCs are immunogenically active [11]. Here, CD274 is linked to neoplasm.